Results of minimal residual disease (MRD) evaluation and MRD-based treatment stratification in childhood ALL

Best Practice and Research: Clinical Haematology

Volumn 15, Issue 4, 2002, Pages 623-638

  Cazzaniga, Giovanni ^a   d'Aniello, Elisabetta ^a   Corral, Lilia ^a   Biondi, Andrea ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Childhood ALL; Minimal residual disease; Treatment stratification

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN; T LYMPHOCYTE RECEPTOR; BCR ABL PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETS TRANSLOCATION VARIANT 6; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL STUDY; ELECTROPHORESIS; FOLLOW UP; GENE REARRANGEMENT; HUMAN; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; QUALITY CONTROL; QUANTITATIVE ASSAY; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE RECEPTOR GENE; TREATMENT OUTCOME; CHROMOSOME TRANSLOCATION; CLONAL VARIATION; DIAGNOSTIC ACCURACY; DISEASE COURSE; DISEASE MARKER; FUSION GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE TARGETING; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REMISSION;

EID: 0036950021     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2002.0228     Document Type: Review

References (70)

1. Szczepanski T, Orfao A, van der Velden VH et al. Minimal residual disease in leukemia patients. Lancet Oncology 2001; 2: 409-417.
2. Campana D & Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 1999; 38: 139-152.
3. Cazzaniga G, Rossi V & Biondi A. Monitoring minimal residual disease using chromosomal translocations in childhood ALL. Baillière's Clinical Haematology 2002; 15: 21-35.
4. Van Dongen JJM, Szczepanski T, De Bruijn MAC et al. Detection of minimal residual disease in acute leukemia patients. Cytokine Molecular Therapy 1996; 2: 121-133.
5. Pongers-Willemse MJ, Seriu T, Stolz F et al. Primers and protocols for standardized MRD detection in ALL using immunoglobulin and T cell receptor gene rearrangements and TALI deletions as PCR targets. Report of the BIOMED-I Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 110-118.
6. Beishuizen A, Hahlen K, Hagemeijer A et al. Multiple rearranged immunoglobulin genes in childhood acute lymphoblastic leukemia of precursor B-cell origin. Leukemia 1991; 5: 657-667.
7. Ghali DW, Panzer S, Fischer S et al. Heterogeneity of the T cell receptor delta gene indicating subclone formation in acute precursorB cell leukemias. Blood 1995; 85: 2795-2801.
8. Steenbergen EJ, Verhagen OJ, Van den Berg H et al. Rearrangement status of the malignant cell determines type of secondary IgH rearrangement (V-replacement or V to DJ joining) in childhood B precursor acute lymphoblastic leukemia. Leukemia 1997; 11: 1258-1265.
9. Wasserman R, Yamada M, Ito Y et al. VH gene rearrangement events can modify the immunoglobulin heavy chain during progression of B-lineage acute lymphoblastic leukemia. Blood 1992; 79: 223-228.
10. Steenbergen EJ, Verhagen OJ, Van Leeuwen EF et al. Distinct ongoing Ig heavy chain rearrangement processes in childhood B-precursor acute lymphoblastic leukemia. Blood 1993; 82: 581-589.
11. Beishuizen A, Verhoeven MA, van Wering ER et al. Analysis of Ig and T cell receptor genes in 40 childhood acute lymphoblastic leukemia at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis. Blood 1994; 83: 2238-2247.
12. Steward CG, Goulden NJ, Katz F et al. A polymerase chain reaction study of the stability of Ig heavy-chain and T cell receptor delta gene rearrangements between presentation and relapse of childhood B-lineage acute lymphoblastic leukemia. Blood 1994; 83: 1355-1362.
13. Taylor JJ, Rowe D, Kylefjord H et al. Characterisation of non-concordance in the T cell receptor gamma chain genes at presentation and clinical relapse in acute lymphoblastic leukemia. Leukemia 1994; 8: 60-66.
14. Baruchel A, Cayuela JM, MacIntyre E et al. Assessment of clonal evolution at Ig/TCR loci in acute lymphoblastic leukaemia by single-strand conformation polymorphism studies and highly resolutive PCR derived methods: implication for a general strategy of minimal residual disease detection. British Journal of Haematology 1995; 90: 85-93.
15. Choi Y, Greenberg SJ, Du TL et al. Clonal evolution in B-lineage acute lymphoblastic leukemia by contemporaneous VH-VH gene replacements and VH-DJH gene rearrangements. Blood 1996; 87: 2506-2512.
16. Lo Nigro L, Cazzaniga G, Di Cataldo A et al. Clonal stability in children with acute lymphoblastic leukemia (ALL) who relapsed five or more years after diagnosis. Leukemia 1999; 13: 190-195.
17. Van Dongen JJ, Seriu T, Panzer-Grumayer ER et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731-1738.
18. van Dongen JJ, Macintyre EA, Gabert JA et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-I Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901-1928.
19. Beishuizen A, De Bruijn MAC, Pongers-Willemse MJ et al. Heterogeneity in junctional regions of immunoglobulin kappa deleting element rearrangements in B cell leukemias: a new molecular target for detection of minimal residual disease. Leukemia 1997; 11: 2200-2207.
20. Biondi A, Champagne M, Rossi V et al. T-cell receptor delta gene rearrangements in childhood T-cell acute lymphoblastic leukemia. Blood 1989; 73: 2133-2138.
21. Biondi A, Francia di Celle P, Rossi V et al. High prevalence of T-cell receptor V delta 2-(D)-D delta 3 or D delta 1/2-D delta 3 rearrangements in B-precursor acute lymphoblastic leukemias. Blood 1990; 75: 1834-1840.
22. van Dongen JJM & Wolvers-Tettero ILM. Analysis of immunoglobulin and T cell receptor genes. Part II: possibilities and limitations in the diagnosis and management of lymphoproliferative diseases and related disorders. Clinical Chimica Acta 1991; 198: 93-174.
23. Beishuizen A, Verhoeven MA, Mol EJ & van Dongen JJM. Detection of immunoglobulin kappa light-chain gene rearrangement patterns by Southern blot analysis. Leukemia 1994; 8: 2228-2236.
24. Breit TM, Beishuizen A, Ludwig WD et al. tal-I deletions in T cell acute lymphoblasticleukemia as PCR target for detection of minimal residual disease. Leukemia 1993; 7: 2004-2011.
25. Landman-Parker J, Aubin J, Delabesse E et al. Simplified strategies for minimal residual disease detection in B cell precursor acute lymphoblastic leukaemia. British Journal of Haematology 1996; 95: 281-290.
26. Bottaro M, Berti E, Biondi A et al. Heteroduplex analysis of T-cell receptor gamma gene rearrangements for diagnosis and monitoring of cutaneous T-cell lymphomas. Blood 1994; 83: 3271-3278.
27. Germano G, Songia S, Biondi A & Basso G. Rapid detection of clonality in patients with acute lymphoblastic leukemia. Haematologica 2001; 86: 382-385.
28. Heid CA, Stevens J, Livak KJ & Williams PM. Real time quantitative PCR. Genome Research 1996; 6: 986-994.
29. Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia 1998; 12: 2006-2014.
30. Verhagen OJ, Willemse MJ, Breunis WB et al. Application of germline IgH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia 2000; 14: 1426-1435.
31. Nakao M, Janssen JW, Flohr T & Bartram CR. Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology. Cancer Research 2000; 60: 3281-3289.
32. Ririe KM, Rasmussen RP & Wittwer CT. Product differentiation by analysis of DNA melting curves during the polymerase chain reaction. Analytical Biochemistry 1997; 245: 154-160.
33. Eckert C, Landt O, Taube T et al. Potential of Light Cycler technology for quantification of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 2000; 14: 316-323.
34. Kreuzer KA, Lass U, Bohn A et al. LightCycler Technology for the quantification of bcr/abl fusion transcripts. Cancer Research 1999; 59: 3171-3174.
35. Bolufer P, Barragan E, Verdeguer A et al. Rapid quantitative detection of TEL-AML1 fusion transcripts in pediatric acute lymphoblastic leukemia by real-time reverse transcription polymerase chain reaction using fluorescently labeled probes. Haematologica 2002; 87: 23-32.
36. Cazzaniga G, Taube T, Rossi V et al. Comparison between TaqMan and LightCycler technology for detection of minimal residual disease in childhood ALL. Hematol J 2001; 1 (suppl. 1): 233a.
37. Biondi A & Masera G. Molecular pathogenesis of childhood acute lymphoblastic leukemia. Haematologica 1998; 83: 651-659.
38. Foroni L, Harrison CJ, Hoffbrand AV et al. Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis. British Journal of Haematology 1999; 105: 7-24.
39. Cave H, van der Werff Ten Bosch J, Suciu S et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. New England Journal of Medicine 1998; 339: 591-598.
40. Jacquy C, Delepaut B, van Daele S et al. A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse. British Journal of Haematology 1997; 98: 140-146.
41. Goulden N, Langlands K, Steward C et al. PCR assessment of bone marrow status in 'isolated' extramedullary relapse of childhood B-precursor acute lymphoblastic leukaemia. British Journal of Haematology 1994; 87: 282-285.
42. Coustan-Smith E, Behm FG, Sanchez J et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998; 351: 550-554.
43. Dworzak MN, Froschl G, Printz D et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002; 99: 1952-1958.
44. Biondi A, Valsecchi MG, Seriu T et al. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM Study Group. Leukemia 2000; 14: 1939-1943.
45. Panzer-Grumayer ER, Schneider M, Panzer S et al. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood 2000; 95: 790-794.
46. Coustan-Smith E, Sancho J, Behm FG et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 2002; 100: 52-58.
47. Neale GA, Menarguez J, Kitchingman GR et al. Detection of minimal residual disease in T-cell acute relapse. Blood 1991; 78: 739-747.
48. Dibenedetto SP, Lo Nigro L, Mayer SP et al. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia. Blood 1997; 90: 1226-1232.
49. Willemse MJ, Seriu T, Hettinger K et al. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood 2002; 99: 4386-4393.
50. Pui CH. Childhood leukaemias. New England Journal of Medicine 1995; 332: 1618-1630.
51. Rabbitts TH. Chromosomal translocations in human cancer. Nature 1994; 372: 143-149.
52. Gabert J, Beillard E, Bi W et al. European standardization and quality control program of Real Time Quantitative RT-PCR analysis of fusion gene transcripts for minimal residual disease detection in leukaemia patients. Blood 2000; 96: 311a.
53. Radich JP. Philadelphia chromosome-positive acute lymphocytic leukemia. Hematology/Oncology Clinics of North America 2001; 15: 21-36.
54. Arico M, Valsecchi MG, Camitta B et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. New England Journal of Medicine 2000; 342: 998-1006.
55. + acute lymphoblastic leukemia (ALL) unravels differences in treatment response. British Journal of Haematology 2002, in press.
56. Mitterbauer G, Nemeth P, Wacha S et al. Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction. British Journal of Haematology 1999; 106: 634-643.
57. Saffroy R, Lemoine A, Brezillon P et al. Real-time quantitation of bcr-abl transcripts in haematological malignancies. European Journal of Haematology 2000; 65: 258-266.
58. Golub TR, Barker GF, Bohlander SK et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the USA 1995; 92: 4917-4921.
59. Romana SP, Mauchaufé M, Le Coniat M et al. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood 1995; 85: 3662-3670.
60. Borkhardt A, Cazzaniga G, Viehmann S et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicentre therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group. Blood 1997; 90: 571-577.
61. Cazzaniga G, Daniotti M, Aloisi A et al. Prospective evaluation of t(12;21) prognostic impact in childhood ALL. Results of the Italian ALL-AIEOP 95 therapy protocol. Blood 2000; 96: 462a.
62. Codrington R, O'Connor HE, Jalali GR et al. Analysis of ETV6/AML1 abnormalities in acute lymphoblastic leukaemia: incidence, alternative spliced forms and minimal residual disease value. British Journal of Haematology 2000; 111: 1071-1079.
63. Shurtleff SA, Buijs A, Behm FG et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with excellent prognosis. Leukemia 1995; 9: 1985-1989.
64. McLean TW, Ringold S, Neuberg D et al. TEL/AML-I dimerises and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood 1996; 88: 4252-4258.
65. Loh ML, Silverman LB, Young ML et al. Incidence of TEL-AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood 1998; 92: 4792-4797.
66. Harbott J, Viehmann S, Borkhardt A et al. Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse. Blood 1997; 90: 4933-4937.
67. Seeger K, Adams HP, Buchwald D et al. TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. The Berlin-Frankfurt-Munster Study Group. Blood 1998; 91: 1716-1722.
68. de Haas V, Oosten L, Dee R et al. Minimal residual disease studies are beneficial in the follow-up of TEL/AML1 patients with B-precursor acute lymphoblastic leukaemia. Journal of Haematology 2000; 111: 1080-1086.
69. Loh ML, Silverman LB, Young ML et al. Incidence of TEL-AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood 1998; 92: 4792-4797.
70. Rubnitz JE, Behm FG, Winchlan D et al. Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favourable prognosis for this genetic subgroup. Leukemia 1999; 13: 19-21.